Citation Information :
Hegazy M, Abo-Elfadl S, Mostafa A, Ibrahim M, Rashed L, Salman A. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2014; 4 (2):59-62.
Background: Liver histology remains the gold standard for assessing nonalcoholic fatty liver disease
(NAFLD). Noninvasive serological markers have been developed to evaluate steatosis to avoid
biopsy. In NAFLD patients, serum resistin was higher than those in control lean and obese patients.
Objective of the study: To investigate serum resistin and its receptor gene expression in liver biopsy
as predictors for NAFLD severity.
Patients and methods: This study was conducted on 54 obese patients, with suspected fatty liver
by ultrasound (excluding diabetic, alcoholic, hepatitis C virus antibody (HCVAb) or hepatitis B surface
antigen (HBsAg) positive patients). They were subjected to anthropometric measurements, laboratory
studies including serum resistin, abdominal ultrasonography (US) and liver biopsy. The 15 lean
subjects were included as a control group. According to biopsy results, patients were subdivided into
nonalcoholic steatohepatitis (NASH) group (46 patients) and non-NASH group (8 patients).
Results: Significantly higher levels of resistin were detected in NAFLD patients compared to control
subjects (p = 0.0001). Also, higher levels of resistin were recorded in NASH group compared
to the non-NASH group; however, the difference was not statistically significant (p = 0.584). Serum
alanine aspirate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl
transpeptidase (GGT) were higher in NASH patients than non-NASH group (p = 0.223, p = 0.005
and p = 0.006 respectively). Abdominal US showed high sensitivity in NAFLD diagnosis (sensitivity
of sonar in detecting steatosis grade compared to biopsy was 61% in grade 1, 25% in grade 2 and
75% in grade 3).
Conclusion: Serum resistin can be combined with other noninvasive markers to predict the presence
of NASH as an alternative to liver biopsy.
Desai P, Tamarapu Parthasarathy P, Galam L, Lockey R, Kolliputi N. A new role for inflammasomes: sensing the disturbances in non-alcoholic fatty liver disease. Front Physiol 2013 Jul 1;4:156
Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013 May 31;11:133
Are we ready for a new epidemic of under recognized liver disease in South Asia especially in Pakistan? Non-alcoholic fatty liver disease. J Pak Med Assoc 2013 Jan;63(1):95-99
Noninvasive investigations for non-alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010 Oct 14;16(38):4784-4791
Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone. PLoS One 2013 Jun 12;8(6):e65543
Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int 2011 Jul;18(2):168-172
Adipocytokines: The pied pipers. J Pharmacol Pharmacother 2010 Jan;1(1):9-17
Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003 Nov;88(11):5452-5455
Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 2005 Jun;41(6):1313-1321
NASH clinical research network a list of members of the nonalcoholic steatohepatitis clinical research network can be found in the appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009 Mar;49(3):809-820
Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques 2008 Apr;44(5):619-626
Analysis of relative gene expression data using real-time quantitative PCR and the 2 [(-delta-delta C (T)] method. Methods 2001 Dec;25(4):402-408
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011 Mar; 16(1):121-36
Patients with nonalcoholic fatty liver disease display increased serum resist in levels and decreased adiponectin levels. Eur J Gastroenterol Hepatol 2009 Jun;21(6):662-666
Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006 Mar;91(3):1081-1086
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008 Nov; 18(11):1430-1437
Role of resistin in inflammation of hepatocytes in non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi 2009 Sep; 17(9):683-687.